Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
The purpose of the study is to evaluate the presence of early vascular aging 6 months and 12 months after COVID-19 infection.
Description: carotid-femoral pulse wave velocity measured by application tonometry
Measure: PWV Time: 6 months after COVID19 infectionDescription: carotid-femoral pulse wave velocity measured by application tonometry
Measure: PWV Time: 12 months after COVID19 infectionDescription: carotid-femoral pulse wave velocity measured by application tonometry
Measure: PWV change Time: difference between PWV at 12 and 6 months after COVID19 infectionDescription: carotid, radial and digital distensibility by standard and ultrahigh frequency ultrasound
Measure: arterial distensibility Time: 6 months after COVID19 infectionDescription: carotid, radial and digital distensibility by standard and ultrahigh frequency ultrasound
Measure: arterial distensibility Time: 12 months after COVID19 infectionDescription: carotid, radial and digital distensibility by standard and ultrahigh frequency ultrasound
Measure: arterial distensibility change Time: difference between arterial distensibility at 12 and 6 months after COVID19 infectionDescription: brachial artery flow-mediated dilation for non-invasive evaluation of endothelial dysfunction, by ultrasound and automatic edge detection analysis
Measure: brachial artery FMD Time: 6 months after COVID19 infectionDescription: brachial artery flow-mediated dilation for non-invasive evaluation of endothelial dysfunction, by ultrasound and automatic edge detection analysis
Measure: brachial artery FMD Time: 12 months after COVID19 infectionDescription: brachial artery flow-mediated dilation for non-invasive evaluation of endothelial dysfunction, by ultrasound and automatic edge detection analysis
Measure: brachial artery FMD change Time: difference between FMD at 12 and 6 months after COVID19 infectionDescription: central blood pressure obtained non-invasively by application tonometry and validated transfer function
Measure: central blood pressure Time: 6 months after COVID19 infectionDescription: central blood pressure obtained non-invasively by application tonometry and validated transfer function
Measure: central blood pressure Time: 12 months after COVID19 infectionDescription: central blood pressure obtained non-invasively by application tonometry and validated transfer function
Measure: central blood pressure (BP) change Time: difference between central BP at 12 and 6 months after COVID19 infectionDescription: peripheral arterial waveform analysis aimed at exploring wave reflection and micro-macrocirculation crosstalk
Measure: wave separation/wave intensity analysis (WSA/WIA) Time: 6 months after COVID19 infectionDescription: peripheral arterial waveform analysis aimed at exploring wave reflection and micro-macrocirculation crosstalk
Measure: wave separation/wave intensity analysis (WSA/WIA) Time: 12 months after COVID19 infectionDescription: peripheral arterial waveform analysis aimed at exploring wave reflection and micro-macrocirculation crosstalk
Measure: WSA/WIA change Time: difference between WSA/WIA at 12 and 6 months after COVID19 infectionDescription: E/e' at rest and after low-level exercise
Measure: cardiac diastolic dysfunction Time: 6 months after COVID19 infectionDescription: E/e' at rest and after low-level exercise
Measure: cardiac diastolic dysfunction Time: 12 months after COVID19 infectionDescription: E/e' at rest and after low-level exercise
Measure: cardiac diastolic dysfunction change Time: difference between cardiac diastolic dysfunction at 12 and 6 months after COVID19 infectionDescription: cardioelastography by ultrafast ultrasound
Measure: myocardial stiffness Time: 6 months after COVID19 infectionDescription: cardioelastography by ultrafast ultrasound
Measure: myocardial stiffness Time: 12 months after COVID19 infectionDescription: cardioelastography by ultrafast ultrasound
Measure: myocardial stiffness change Time: difference between myocardial stiffness at 12 and 6 months after COVID19 infectionDescription: individual data will be meta-analyzed with sister studies running in parallel worldwide
Measure: total mortality Time: 2 yearsDescription: individual data will be meta-analyzed with sister studies running in parallel worldwide
Measure: total mortality Time: 5 yearsDescription: individual data will be meta-analyzed with sister studies running in parallel worldwide
Measure: total mortality Time: 10 yearsDescription: fatal+non-fatal
Measure: CV events Time: 2 yearsDescription: fatal+non-fatal
Measure: CV events Time: 5 yearsDescription: fatal+non-fatal
Measure: CV events Time: 10 yearsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports